Torres-Torres J, Nieto-Vázquez E, Maldonado-Nájera LF, Coronel-Cruz FM, Vargas-Ruiz RL, Rojas-Zepeda L, García-Mandujano R, Martínez-Cisneros RA

Language: Spanish
References: 22
Page: 792-801
PDF size: 398.90 Kb.

ABSTRACT

Objective: Calculate and adjust the multiples of the median (MoMs) for the mean pulsatility index of uterine arteries (IPm Aut), mean arterial pressure (PAM), placental growth factor (PlGF) and plasma protein associated with pregnancy (PAPP-A), in order to assess the diagnostic performance of the corrected preeclampsia model of the fetal medicine foundation in the Mexican population.
Materials and Methods: Case-control study nested in a prospective cohort conducted at the “Dr. Galo Soberón y Parra ”from October 1, 2015 - June 30, 2016. Patients with pregnancy of 11-13.6 weeks were included, multiple pregnancies or older than 14 weeks were excluded and patients with medication intake prior to pregnancy; Patients who decided to leave the study were eliminated. Autm IPm, PAM, PlGF and PAPP-A serum values were evaluated. The difference in the distribution of biomarkers between that observed in the Mexican population and that expected was compared according to the original formula of the Fetal Medicine Foundation. When the difference was greater than 0.2 MoMs, the median observed was used as an adjustment coefficient to the original expected formula.
Results: Of the 300 patients recruited, 292 concluded the study. The average gestational age at the time of screening was 12.4 weeks (standard deviation [SD] 0.72). The prevalence of preeclampsia was 4.5% (13/292). Important differences were found in the distribution of multiples of the median (MoMs) for IPm Aut, PlGF and PAPP-A. After correction of the biomarkers, the sensitivity, false positives and area under the curve (AUC) of the model adjusted to detect any preeclampsia was 92% (12/13), 5.7% (16/279) and 93.3%, respectively .
Conclusions: The distribution of MoMs in the Mexican population is different for the PlGF, PAPP-A and IPm Aut biomarkers. The adjustment of these biomarkers to the Mexican population results in a good diagnostic performance of the preeclampsia model.

REFERENCES

1. Guía de Práctica Clínica. Detección y diagnóstico de enfermedades hipertensivas del embarazo. Catalogo maestro de GPC CENETEC. 2017 1-57. http://www.cenetec.salud.gob. mx/contenidos/gpc/catalogoMaestroGPC.html#

2. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early versus late. Onset disease. Am J Obstet Gynecol. 2013 Dec;209 (6): 544. e1-544.e12. https://doi.org/10.1016/j.ajog.2013.08.019

3. Nicolaides KH. Turning the Pyramid of Prenatal Care. Fetal Diagn Ther 2011: 29(3):183-196. DOI: https://doi. org/10.1159/000324320

4. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH: Prediction of preeclampsia from biophysical and biochemical markers at 11-13 weeks. PrenatDiagn 2011; 31(1):66-74. DOI: https://doi.org/10.1002/pd.2660

5. Sotiriadis A, Hernandez-Andrade E, da Silva Costa F, Ghi T, GlancP, Khalil A, Martins WP, Odibo AO, Papageorghiou AT, Salomon LJ, Thilaganathan B. ISUOG Practice Guidelines: role of ultrasound in screening for and follow-up of preeclampsia. Ultrasound Obstet Gynecol. 2019 Jan;53(1):7- 22. DOI: https://doi.org/10.1002/uog.20105

6. American College of Obstetricians and Gynecologists Committee on Practice Bulletins–Obstetrics. ACOG Practice bulletin No. 202: Gestational hypertension and preeclampsia: DOI: https://doi.org/10.1097/AOG.0000000000003018

7. CONEVAL (Consejo Nacional de Evaluación de la Política de Desarrollo Social). Evaluación Estratégica sobre Mortalidad Materna en México 2010: Características sociodemográficas que obstaculizan a las mujeres embarazadas su acceso efectivo a instituciones de salud. México, DF: CONEVAL, 2012; 45-69. http://www. coneval.org.mx/Informes/Evaluacion/Mortalidad%20 materna%202010/INFORME_MORTALIDAD_MATERNA. pdf#search=evaluacion%20estrategica%20sobre%20 mortalidad%20materna%202010

8. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, Van Asshe A. A study of placental bed spiral arteries and trophoblastic invasion in normal and severe pre-eclampsia pregnancies. Br J ObstetGynaecol 1994: 101: 669-674. DOI: https://doi.org/10.1111/j.1471-0528.1994.tb13182.x

9. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicoladies KH: Uterine Artery Doppler at 11-13+6 weeks in the prediction of preeclampsia. Ultrasound ObstetGynecol 2007; 30(5): 742-749. DOI: https://doi.org/10.1002/uog.5157

10. Poon LC, Kametes NA, Valencia C, Chelemen T, Nicolaides KH: Hypertensive disorders in pregnancy: screening by systolic diastolic and mean arterial pressure at 11-13 weeks. Hypertens Pregnancy 2011; 30(1): 93-107. DOI: https:// doi.org/10.3109/10641955.2010.484086

11. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH: First trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53(5):812-818. DOI: https://doi. org/10.1161/HYPERTENSIONAHA.108.127977

12. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère: Prevention of Preeclampsia and Intrauterine Growth Restriction with aspirin started in early pregnancy. A Meta-Analysis. Obset&Gynecol 2010; 116(2-1):402-414. DOI: https://doi.org/10.1097/ AOG.0b013e3181e9322a

13. Roberge S, Nicolaides K, Demers S, Villas P, Bujold E. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2013; 41:491-499. DOI: https://doi.org/10.1002/ uog.12421

14. Costa F, Panagodage S, Brennecke S and Murthi P. Low-dose aspirin improves trophoblastic function in early-onset preeclampsia. AJOG 2014: Poster Session II, S145 (274).DOI: https://doi.org/10.1016/j.ajog.2013.10.307

15. Park F, Russo K, Pellosi M, et al. The impact of aspirin on the prevalence of early onset pre-eclampsia after first trimester screening. Prenat Diagn. 2015; oct;46)4:419-423. DOI: https://doi.org/10.1002/uog.14819

16. T. M. Reynolds and M. D. Penney, “The Mathematical Basis of Multivariate Risk Screening: With Special Reference to Screening for Down’s Syndrome Associated Pregnancy,” Ann. Clin. Biochem. An Int. J. Biochem. Lab. Med., vol. 27, no. 5, pp. 452–458, Sep. 1990. DOI: https://doi. org/10.1177/000456329002700506

17. Chitty L and Lau T. First trimester screening–new directions for antenatal care. PrenatDiag 2011; 31:1-2. DOI: https:// doi.org/10.1002/pd.2695

18. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in earley screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33(1):8-15. DOI: https://doi.org/10.1159/000341264

19. Karagiannis, G., Akolekar, R., Sarquis, R., Wright, D. and Nicolaides, K.H. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11 - 13 weeks. Fetal Diagnosis and Therapy, 2011;29(2), 148-154. DOI: https://doi.org/10.1159/000321694

20. Poon L, Syngelaki A, Akolekar R, Lai J and Nicolaides K. Combined Screening for Preeclampsia and Small for Gestational Age at 11–13 Weeks. Fetal Diagn ther 2013; 33(1):16-27. DOI: https://doi.org/10.1159/000341712

21. Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH. Maternal serum placental growth factor, pregnancy associated plasma protein-a and free B-human chorionic gonadotrophin at 30-33 weeks in the prediction of preeclampsia. Fetal Diagn Ther. 2013;33(3):164-172. DOI: https://doi. org/10.1159/000345090

22. Oviedo-Cruz H, Reyes-Mendoza MA, Mestizo-Reyes V. Corrección de medianas de la fracción beta libre de gonadotrofina coriónica humana y proteína plasmática A del embarazo del primer trimestre para una muestra de población mexicana. Ginecol Obstet Mex. 2017 diciembre; 85(12):787-798. DOI: https://doi.org/10.24245/gom. v85i12.994